Breaking
World

New Saltation COVID-19 Variant PJ.2.1 Spreads Internationally

Scientists have identified PJ.2.1, a heavily mutated "saltation" variant of SARS-CoV-2 that originated from the JN.1 lineage. While findings published in the Journal of Infection show increased cellular binding efficiency, public health experts emphasize there is currently no evidence that PJ.2.1 causes more severe illness than other circulating strains.

New Saltation COVID-19 Variant PJ.2.1 Spreads Internationally
AI generated image | MinuteBrief Team

In This Story

In Brief

  1. Described by virologists as a saltation variant, PJ.2.1 emerged with a large cluster of genetic changes in its spike protein rather than accumulating mutations gradually.
  2. First detected in Ontario, Canada in May 2026, the lineage has since been sequenced in the U.S., France, Spain, Singapore, Australia, New Zealand, and Israel.
  3. Epidemiological data indicates a higher frequency of detection among individuals aged 70 and older.
  4. Laboratory testing shows PJ.2.1 exhibits enhanced ACE2 receptor binding efficiency, though antibody evasion remains moderate compared to other current lineages.

Emergence and Genetic Profile of PJ.2.1

Epidemiologists and virologists are tracking the international spread of PJ.2.1, a novel descendant of the JN.1 coronavirus lineage (specifically originating from MC.10.1.7).

According to preliminary findings published by Markus Hoffmann and colleagues in the Journal of Infection, PJ.2.1 is classified as a "saltation variant"—a term used for viral strains that undergo significant genetic leaps in short periods. The variant features a heavily mutated spike protein, the primary structural component used by the virus to attach to and penetrate human target cells.

Epidemiological Footprint and Age Profile

The earliest documented sample of PJ.2.1 was sequenced in Ontario, Canada, on May 2, 2026. By late June, the strain was recorded in New York City and quickly expanded across several U.S. states including California, Florida, and Arizona. In Europe, researchers in Spain reported evidence of active local transmission chains across multiple regions.

Genomic surveillance data from Public Health Ontario demonstrates its rapid rise, with PJ.2.1 accounting for 25.2% of sequenced SARS-CoV-2 cases by mid-October 2026, up from 16.9% in the preceding period. Analysis of patient demographics indicates that PJ.2.1 disproportionately infects older populations, particularly individuals aged 70 and above.

Virological Characteristics and Immune Evasion

Laboratory analyses indicate that the mutations in PJ.2.1 enhance its binding affinity to human ACE2 receptors, allowing higher cell-entry efficiency compared to earlier variants like LP.8.1.

However, health officials emphasize that higher binding affinity does not automatically translate to increased disease severity. Crucially, tests revealed that PJ.2.1 does not show significant evasion of neutralising antibodies generated by recent updated vaccines, suggesting that current seasonal boosters remain effective at preventing severe outcomes.

Next Steps

Public health agencies worldwide, including the WHO and regional genomic surveillance networks, are keeping PJ.2.1 under active observation. Health authorities continue to recommend routine diagnostic testing and seasonal vaccination for vulnerable groups as winter approaches.

More from World